Repository logo

Predictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre — Uganda

dc.contributor.authorNyeko, Richard
dc.contributor.authorGeriga, Fadhil
dc.contributor.authorAngom, Racheal
dc.contributor.authorKambugu, Joyce Balagadde
dc.contributor.authorHeerden, Jaques van
dc.date.accessioned2026-01-30T08:33:54Z
dc.date.issued2025
dc.description.abstractBackground The treatment outcomes for children and adolescents with rhabdomyosarcoma (RMS) in low-income countries are poor. However, there is a paucity of literature on RMS and its management outcomes in low-resource settings. We evaluated the treatment of RMS with the aim of identifying prognostic factors during management to improve outcomes. Methods We sourced data on children under 18 years treated for rhabdomyosarcoma at the Uganda Cancer Institute between January 2016 and December 2020. Kaplan-Meier survival analysis and Cox’s proportional hazards model were used for five-year survival analysis. Results One hundred twenty-eight RMS cases were identified, with a median age of 6.0 years (IQR 3.6–10.0). The most common primary tumour site was the head and neck region, comprising non-parameingeal sites, 37 (28.9%); parameingeal sites, 32 (25.0%); and orbital tumours, 17 (13.3%). Overall, 68 (53.1%) of the primary tumour sites were unfavourable sites. Seventeen (13.3%) patients had metastatic disease at diagnosis, primarily to the lungs, 11 (64.8%). Embryonal and alveolar RMS accounted for 50.0% and 20.3% of the cases, respectively. Only 31 (24.2%) of the patients underwent surgery, and 36 (28.1%) were irradiated. The treatment completion rate was 33.6%, while 46.1% abandoned treatment. Only 25 (19.5%) patients were alive at the time of the study, 65 (50.8%) had died, and 38 (29.7%) had an unknown status. The five-year overall and event-free survival rates were 35% and 30%, respectively. Orbital primary tumour site (HR = 2.86; 95% CI 1.12–7.31; p = 0.028), metastatic disease (HR = 4.09; 95% CI 2.01–8.31; p < 0.001), elevated serum lactate dehydrogenase at diagnosis above 400 U/L (HR = 2.80; 95% CI 1.46–5.33; p = 0.002), and lack of local control (HR = 3.33; 95% CI 1.34–8.29; p = 0.010) were significant factors for poor survival. Conclusion Rhabdomyosarcoma outcomes in Ugandan children are largely poor, with high treatment abandonment and mortality. Concerted, multidisciplinary efforts are needed to improve outcomes in this setting. Keywords Rhabdomyosarcoma, Children, Adolescents, Outcomes, Resource-limited contexts
dc.identifier.citationNyeko, R., Geriga, F., Angom, R., Kambugu, J. B., & Van Heerden, J. (2025). Predictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre—Uganda. BMC cancer, 25(1), 1299.
dc.identifier.urihttps://doi.org/10.1186/s12885-025-14735-3
dc.identifier.urihttps://ir.lirauni.ac.ug/handle/123456789/935
dc.language.isoen
dc.publisherBMC cancer
dc.subjectRhabdomyosarcoma
dc.subjectChildren
dc.subjectAdolescents
dc.subjectOutcomes
dc.subjectResource-limited contexts
dc.titlePredictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre — Uganda
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Nyeko_FoM_Article_Predictors_2025.pdf
Size:
2.49 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: